Profile of patients with diabetes treated with insulin lispro 200 U/mL: a real-world study from Spain

Miriam Rubio de Santos¹, Esther Artime¹, Natalia Duque¹, Silvia Díaz-Cerezo¹, Erik Spaepen², Ágata Carreño³, Alberto Fernández⁴

¹ Eli Lilly and Company, Alcobendas, Madrid, Spain
² HaaPACS GmbH, Schriesheim, Germany
³ IQVIA, Madrid, Spain
⁴ Department of Endocrinology and Nutrition, Móstoles University Hospital, Madrid, Spain

Correspondence: Miriam Rubio de Santos
Eli Lilly and Company, Avda. de la Industria 30, Alcobendas 28108, Madrid, Spain
Phone: +34 91 663 5194
Email: Rubio_miriam@lilly.com
Supplementary Methods

Variables

Patient sociodemographic and clinical characteristics were derived from available data at the index date or from the last data available before the index date. Patient sociodemographic characteristics included were: age, sex, body mass index (BMI), date of first diabetes record in the database, relevant laboratory data (glycated hemoglobin [HbA1c], estimated glomerular filtration rate, glycemia, cholesterol, and triglycerides), and diabetes-associated comorbidities (including hypertension, hyperlipidemia, cardiovascular diseases, chronic kidney disease, microalbuminuria, and retinopathy). Previous antihyperglycemic treatments were analyzed based on prescriptions registered any time before the index date, including all records since the date of diagnosis or date of first record in the database (for patients diagnosed before 2008). Data on IL200 daily dose and posology and IL200 prescriber (primary care physician or specialist) at index date were also obtained. Information on insulin (mixed, rapid, and basal) and noninsulin antihyperglycemic prescriptions (oral antihyperglycemic drugs [OADs] and other injectables such as glucagon-like peptide 1 receptor agonists [GLP-1 RAs]) was extracted for the following time frames: between the first diabetes record in the database and the index date, within 90 days before the index date, and, for concomitant prescriptions, at or within 60 days after the index date. Insulin dose was extracted for antihyperglycemic prescriptions available within 90 days before and 60 days after index. Total daily dose of insulin (units of insulin [UI]/day) was calculated as the mean of available insulin prescriptions in the 90 days prior to the index date. Total daily dose of insulin was described according to the type of insulin prescribed: basal only, rapid only, basal+rapid, and mixed or other combinations. The total daily dose of rapid insulin (UI/day) was described in patients with rapid insulin or basal+rapid insulin prescriptions. For IL200, the prescribed dose at index date in U/day and the percentage of patients who initiated IL200 under 20 U/day were obtained. All the variables were extracted from the IQVIA EMR database. Some derived variables and endpoints were calculated based on the variables extracted.
**Database**

The IQVIA EMR database has collected longitudinal anonymized patient data nationally since 2008. It contains the EMRs of patients collected by a constant panel of over 1,500 primary care physicians and 2,000 secondary care physicians of all specialties who are equipped with IQVIA’s EMR software. The active patients in the database represent around 3% of the Spanish population (1.2 million people from three geographical regions and including all sexes and age groups). Patient data are uploaded and delivered to IQVIA monthly through an electronic link containing the full anonymized data of every patient in participating practices. The patient identifier is unique throughout all primary care and specialist practices. The information collected in the IQVIA EMR database includes demographic and clinical data of the patients such as age, sex, BMI, laboratory test results, diagnosis (ICD-9), comorbidities, and medication prescriptions. It also includes data on the prescriber profile (primary or secondary care), specialty, dates of treatment, and referrals.

Although the IQVIA EMR database contains information on diagnosis since 2008, full prescription records have only been collected in the database since 2013, meaning that treatment records may have been partial if diagnosis occurred before 2013; this could result in the overrepresentation of the total number of nontreated patients. Additionally, a diagnosis date file was not available in the database, so we used the first diabetes record in the database. Consequently, this approach resulted in an underestimation of the time from diagnosis for patients diagnosed before 2008. The amount of data missing from the database may have led to underreporting of weight, since this parameter may be more frequently documented when there is a change or when the weight is above normal. This would result in an overrepresentation of high BMI values. Missing data for HbA1c levels could also have biased the database towards more extreme values. Another possible explanation of underreporting of BMI or HbA1c is therapeutic inertia, which is sometimes observed in chronic conditions such as diabetes. Finally, since data in this study were derived from an EMR database, the dates of prescriptions may not accurately represent treatment dates in some cases.
**Figure S1.** Patient disposition. The inclusion period was June 1, 2015, to December 31, 2019. The index date was the date of start of treatment with IL200. EMR, electronic medical records; IL200, insulin lispro 200 U/mL; T1D, type 1 diabetes; T2D, type 2 diabetes

Patients in IQVIA EMR database
N=1,175,000

- Patients with diabetes N=101,348
  - Patients with T1D N=6,704
    - Patients with T1D treated with diabetes therapies N=6,704
      - Excluded: Patients not treated with IL200 within the inclusion period N=6,633
    - Patients with T1D who initiated treatment with IL200 within the inclusion period N=71
      - Excluded: Patients aged <18 years at index date N=6
  - Adult patients with T1D included in the study N=65

- Patients with T2D N=94,644
  - Patients with T2D treated with diabetes therapies N=76,317
    - Excluded: Patients with T2D not treated with diabetes therapies N=18,327
  - Patients with T2D who initiated treatment with IL200 within the inclusion period N=168
    - Excluded: Patients aged <18 years at index date N=1
  - Adult patients with T2D included in the study N=167

Excluded: Patients not treated with IL200 within the inclusion period N=76,149
Excluded: Patients aged <18 years at index date N=6
Table S1. Antihyperglycemic prescriptions any time before IL200 initiation, N (%)

| Variable     | Prescription              | T1D (N=54) | T2D (N=164) | Total (N=218) |
|--------------|---------------------------|------------|-------------|---------------|
| Insulin      | Total insulin<sup>a</sup> | 52 (96.3)  | 148 (90.2)  | 200 (91.7)    |
|              | Basal insulin             | 49 (90.7)  | 135 (82.3)  | 184 (84.4)    |
|              | Degludec (Tresiba<sup>®</sup>) | 6 (11.1)   | 6 (3.7)     | 12 (5.5)      |
|              | Detemir (Levemir<sup>®</sup>) | -           | 23 (14.0)   | 23 (10.6)     |
|              | Glargine                  | 45 (83.3)  | 119 (72.6)  | 164 (75.2)    |
|              | (Abasaglar<sup>®</sup>)   | -           | 7 (4.3)     | 7 (3.2)       |
|              | (Lantus<sup>®</sup>)      | 43 (79.6)  | 99 (60.4)   | 142 (65.1)    |
|              | (Toujeo<sup>®</sup>)      | 17 (31.5)  | 38 (23.2)   | 55 (25.2)     |
|              | Human                     | 1 (1.9)    | 17 (10.4)   | 18 (8.3)      |
|              | (Humulina NPH<sup>®</sup>)| -           | 3 (1.8)     | 3 (1.4)       |
|              | (Insulatard NPH<sup>®</sup>) | 1 (1.9)    | 14 (8.5)    | 15 (6.9)      |
|              | Lispro (Humalog basal<sup>®</sup>) | 2 (3.7)    | 6 (3.7)     | 8 (3.7)       |
| Mixed insulin|                           | 14 (25.9)  | 53 (32.3)   | 67 (30.7)     |
|              | Aspart (Novomix<sup>®</sup>) | 4 (7.4)    | 32 (19.5)   | 36 (16.5)     |
|              | Human                     | 3 (5.6)    | 3 (1.8)     | 6 (2.8)       |
|              | (Humulina 30 70<sup>®</sup>) | 1 (1.9)    | -           | 1 (0.5)       |
|              | (Mixtard<sup>®</sup>)     | 2 (3.7)    | 3 (1.8)     | 5 (2.3)       |
|              | Lispro (Humalog mix<sup>®</sup>) | 7 (13.0)  | 23 (14.0)   | 30 (13.8)     |
| Rapid insulin|                           | 44 (81.5)  | 102 (62.2)  | 146 (67.0)    |
|              | Aspart (Novorapid<sup>®</sup>)<sup>a</sup> | 17 (31.5)  | 59 (36.0)   | 76 (34.9)     |
|              | Glulisine (Apidra<sup>®</sup>) | 2 (3.7)    | 8 (4.9)     | 10 (4.6)      |
|              | Human                     | 1 (1.9)    | 15 (9.1)    | 16 (7.3)      |
|              | (Actrapid<sup>®</sup>)    | 1 (1.9)    | 13 (7.9)    | 14 (6.4)      |
|              | (Humulina<sup>®</sup>)    | -          | 2 (1.2)     | 2 (0.9)       |
| Lispro       |                           | 26 (48.1)  | 32 (19.5)   | 58 (26.6)     |
| Variable                      | Prescription                  | T1D (N=54) | T2D (N=164) | Total (N=218) |
|------------------------------|-------------------------------|------------|-------------|--------------|
| (Humalog 100®)              |                               | 26 (48.1)  | 28 (17.1)   | 54 (24.8)    |
| (Humalog Junior KwikPen®)   |                               | -          | 1 (0.6)     | 1 (0.5)      |
| (Humalog vial®)             |                               | -          | 5 (3.0)     | 5 (2.3)      |

| Noninsulin treatments       |                               |            |             |              |
|------------------------------|-------------------------------|------------|-------------|--------------|
| Total noninsulin antidiabetics |                               | 7 (13.0)  | 160 (97.6) | 167 (76.6)   |
| Total metformin              |                               | 5 (9.3)    | 141 (86.0) | 146 (67.0)   |
| Total canagliflozin          |                               | -          | 9 (5.5)    | 9 (4.1)      |
| Total dapagliflozin          |                               | 2 (3.7)    | 23 (14.0)  | 25 (11.5)    |
| Total empagliflozin          |                               | 2 (3.7)    | 21 (12.8)  | 23 (10.6)    |
| Total linagliptin            |                               | -          | 37 (22.6)  | 37 (17.0)    |
| Total sitagliptin            |                               | -          | 45 (27.4)  | 45 (20.6)    |
| Total vildagliptin           |                               | -          | 31 (18.9)  | 31 (14.2)    |
| AGI (repaglinide)            |                               | 1 (1.9)    | 16 (9.8)   | 17 (7.8)     |
| DPP4 inhibitors              |                               | -          | 48 (29.3)  | 48 (22.0)    |
| Alogliptin                   |                               | -          | 3 (1.8)    | 3 (1.4)      |
| Linagliptin                  |                               | -          | 29 (17.7)  | 29 (13.3)    |
| Sitagliptin                  |                               | -          | 14 (8.5)   | 14 (6.4)     |
| Vildagliptin                 |                               | -          | 5 (3.0)    | 5 (2.3)      |
| DPP4 inhibitors + metformin  |                               | -          | 74 (45.1)  | 74 (33.9)    |
| Alogliptin + metformin       |                               | -          | 2 (1.2)    | 2 (0.9)      |
| Linagliptin + metformin      |                               | -          | 11 (6.7)   | 11 (5.0)     |
| Saxagliptin + metformin      |                               | -          | 2 (1.2)    | 2 (0.9)      |
| Sitagliptin + metformin      |                               | -          | 38 (23.2)  | 38 (17.4)    |
| Vildagliptin + metformin     |                               | -          | 30 (18.3)  | 30 (13.8)    |
| Glitazone (pioglitazone)     |                               | -          | 3 (1.8)    | 3 (1.4)      |
| Glitazone + DPP4 inhibitors  |                               | -          | 1 (0.6)    | 1 (0.5)      |
| Variable                     | Prescription                  | T1D (N=54) | T2D (N=164) | Total (N=218) |
|------------------------------|-------------------------------|------------|-------------|---------------|
| Pioglitazone + alogliptin    | -                             | 1 (0.6)    | 1 (0.5)     |               |
| GLP-1 RAs                    | -                             | 29 (17.7)  | 29 (13.3)   |               |
| Dulaglutide                  | -                             | 10 (6.1)   | 10 (4.6)    |               |
| Exenatide                    | -                             | 11 (6.7)   | 11 (5.0)    |               |
| Liraglutide                  | -                             | 13 (7.9)   | 13 (6.0)    |               |
| Lixisenatide                 | -                             | 3 (1.8)    | 3 (1.4)     |               |
| Metformin                    | 4 (7.4)                       | 114 (69.5) | 118 (54.1)  |               |
| SGLT2 inhibitors             | 3 (5.6)                       | 28 (17.1)  | 31 (14.2)   |               |
| Canagliflozin                | -                             | 4 (2.4)    | 4 (1.8)     |               |
| Dapagliflozin                | 1 (1.9)                       | 11 (6.7)   | 12 (5.5)    |               |
| Empagliflozin                | 2 (3.7)                       | 15 (9.1)   | 17 (7.8)    |               |
| SGLT2 inhibitors + metformin | 1 (1.9)                       | 26 (15.9)  | 27 (12.4)   |               |
| Canagliflozin + metformin    | -                             | 6 (3.7)    | 6 (2.8)     |               |
| Dapagliflozin + metformin    | 1 (1.9)                       | 14 (8.5)   | 15 (6.9)    |               |
| Empagliflozin + metformin    | -                             | 8 (4.9)    | 8 (3.7)     |               |
| Sulfonylureas                | 43 (26.2)                     | 43 (19.7)  |             |               |
| Glibenclamide                | -                             | 12 (7.3)   | 12 (5.5)    |               |
| Gliclazide                   | -                             | 22 (13.4)  | 22 (10.1)   |               |
| Glimepiride                  | -                             | 13 (7.9)   | 13 (6.0)    |               |
| Gliquidone                   | -                             | 1 (0.6)    | 1 (0.5)     |               |

Multiple responses were permitted. Percentages were calculated over the total patients in each column.

a No Fiasp® prescriptions were reported

b Alone or in combination

AGI, alpha-glucosidase inhibitors; DPP4, dipeptidyl peptidase 4; GLP-1 RA, glucagon-like peptide-1 receptor agonist; IL200, insulin lispro 200 U/mL; NPH, neutral protamine Hagedorn; SGLT2, sodium-glucose co-transporter 2; T1D, type 1 diabetes; T2D, type 2 diabetes
| Variable        | Prescription                      | T1D (N=54) | T2D (N=164) | Total (N=218) |
|-----------------|-----------------------------------|------------|-------------|---------------|
| Insulin         | Total insulin<sup>a</sup>          | 48 (88.9)  | 131 (79.9)  | 179 (82.1)    |
|                 | Basal insulin                     | 40 (74.1)  | 107 (65.2)  | 147 (67.4)    |
|                 | Degludec (Tresiba<sup>®</sup>)     | 6 (11.1)   | 5 (3.0)     | 11 (5.0)      |
|                 | Detemir (Levemir<sup>®</sup>)      | -          | 6 (3.7)     | 6 (2.8)       |
|                 | Glargine                          | 33 (61.1)  | 93 (56.7)   | 126 (57.8)    |
|                 | (Abasaglar<sup>®</sup>)           | -          | 4 (2.4)     | 4 (1.8)       |
|                 | (Lantus<sup>®</sup>)              | 17 (31.5)  | 58 (35.4)   | 75 (34.4)     |
|                 | (Toujeo<sup>®</sup>)              | 16 (29.6)  | 32 (19.5)   | 48 (22.0)     |
|                 | Human                             | -          | 5 (3.0)     | 5 (2.3)       |
|                 | (Humulina NPH<sup>®</sup>)        | -          | 1 (0.6)     | 1 (0.5)       |
|                 | (Insulatard NPH<sup>®</sup>)      | -          | 4 (2.4)     | 4 (1.8)       |
|                 | Lispro (Humalog basal<sup>®</sup>)| 1 (1.9)    | 2 (1.2)     | 3 (1.4)       |
| Mixed insulin   |                                   | 7 (13.0)   | 31 (18.9)   | 38 (17.4)     |
|                 | Aspart (Novomix<sup>®</sup>)      | 2 (3.7)    | 15 (9.1)    | 17 (7.8)      |
|                 | Human (Mixtard<sup>®</sup>)       | 1 (1.9)    | 1 (0.6)     | 2 (0.9)       |
|                 | Lispro (Humalog mix<sup>®</sup>)  | 4 (7.4)    | 16 (9.8)    | 20 (9.2)      |
| Rapid insulin   |                                   | 32 (59.3)  | 65 (39.6)   | 97 (44.5)     |
|                 | Aspart (Novorapid<sup>®</sup>)<sup>a</sup> | 15 (27.8) | 33 (20.1) | 48 (22.0)     |
|                 | Glulisine (Apidra<sup>®</sup>)    | 1 (1.9)    | 6 (3.7)     | 7 (3.2)       |
|                 | Human                             | -          | 7 (4.3)     | 7 (3.2)       |
|                 | (Actrapid<sup>®</sup>)            | -          | 5 (3.0)     | 5 (2.3)       |
|                 | (Humulina<sup>®</sup>)            | -          | 2 (1.2)     | 2 (0.9)       |
|                 | Lispro                            | 16 (29.6)  | 20 (12.2)   | 36 (16.5)     |
|                 | (Humalog 100<sup>®</sup>)         | 16 (29.6)  | 16 (9.8)    | 32 (14.7)     |
|                 | (Humalog Junior KwikPen<sup>®</sup>) | -            | 1 (0.6)   | 1 (0.5)      |
| Variable | Prescription | T1D (N=54) | T2D (N=164) | Total (N=218) |
|----------|--------------|------------|------------|--------------|
| (Humalog vial®) | - | 3 (1.8) | 3 (1.4) |
| **Noninsulin treatments** | | | | |
| Total noninsulin antidiabetics | | 5 (9.3) | 125 (76.2) | 130 (59.6) |
| Total metformin<sup>b</sup> | | 2 (3.7) | 88 (53.7) | 90 (41.3) |
| Total canagliflozin<sup>b</sup> | - | 7 (4.3) | 7 (3.2) |
| Total dapagliflozin<sup>b</sup> | | 2 (3.7) | 16 (9.8) | 18 (8.3) |
| Total empagliflozin<sup>b</sup> | | 2 (3.7) | 12 (7.3) | 14 (6.4) |
| Total linagliptin<sup>b</sup> | - | 25 (15.2) | 25 (11.5) |
| Total sitagliptin<sup>b</sup> | - | 21 (12.8) | 21 (9.6) |
| Total vildagliptin<sup>b</sup> | - | 9 (5.5) | 9 (4.1) |
| AGI (repaglinide) | - | 7 (4.3) | 7 (3.2) |
| **DPP4 inhibitors** | | 27 (16.5) | 27 (12.4) |
| Alogliptin | - | 1 (0.6) | 1 (0.5) |
| Linagliptin | - | 18 (11.0) | 18 (8.3) |
| Sitagliptin | - | 6 (3.7) | 6 (2.8) |
| Vildagliptin | - | 2 (1.2) | 2 (0.9) |
| **DPP4 inhibitors + metformin** | | 30 (18.3) | 30 (13.8) |
| Alogliptin + metformin | - | 1 (0.6) | 1 (0.5) |
| Linagliptin + metformin | - | 7 (4.3) | 7 (3.2) |
| Sitagliptin + metformin | - | 15 (9.1) | 15 (6.9) |
| Vildagliptin + metformin | - | 7 (4.3) | 7 (3.2) |
| **GLP-1 RAs** | | 16 (9.8) | 16 (7.3) |
| Dulaglutide | - | 8 (4.9) | 8 (3.7) |
| Exenatide | - | 4 (2.4) | 4 (1.8) |
| Liraglutide | - | 4 (2.4) | 4 (1.8) |
| Metformin | 1 (1.9) | 41 (25.0) | 42 (19.3) |
| **SGLT2 inhibitors** | 3 (5.6) | 16 (9.8) | 19 (8.7) |
| Variable | Prescription | T1D (N=54) | T2D (N=164) | Total (N=218) |
|----------|--------------|------------|-------------|--------------|
| Canagliflozin | -            | 3 (1.8)    | 3 (1.4)     |
| Dapagliflozin | 1 (1.9)      | 7 (4.3)    | 8 (3.7)     |
| Empagliflozin | 2 (3.7)      | 6 (3.7)    | 8 (3.7)     |
| SGLT2 inhibitors + metformin | 1 (1.9) | 19 (11.6) | 20 (9.2) |
| Canagliflozin + metformin | -          | 4 (2.4)    | 4 (1.8)     |
| Dapagliflozin + metformin | 1 (1.9)      | 9 (5.5)    | 10 (4.6)    |
| Empagliflozin + metformin | -           | 6 (3.7)    | 6 (2.8)     |
| Sulfonylureas | -            | 8 (4.9)    | 8 (3.7)     |
| Glibenclamide | -            | 2 (1.2)    | 2 (0.9)     |
| Gliclazide | -            | 6 (3.7)    | 6 (2.8)     |

Multiple responses were permitted. Percentages were calculated over the total patients in each column.

<sup>a</sup> No Fiasp<sup>®</sup> prescriptions were reported

<sup>b</sup> Alone or in combination

AGI, alpha-glucosidase inhibitors; DPP4, dipeptidyl peptidase 4; GLP-1 RA, glucagon-like peptide-1 receptor agonist; IL200, insulin lispro 200 U/mL; NPH, neutral protamine Hagedorn; SGLT2, sodium glucose co-transporter 2; T1D, type 1 diabetes; T2D, type 2 diabetes
Table S3. Antihyperglycemic prescriptions within 60 days of IL200 initiation (IL200 not included), N (%)

| Variable                  | Prescription                   | T1D (N=65) | T2D (N=167) | Total (N=232) |
|---------------------------|--------------------------------|------------|-------------|---------------|
| **Insulin**               |                                |            |             |               |
| Total insulin             |                                | 57 (87.7)  | 147 (88.0)  | 204 (87.9)    |
| Basal insulin            |                                | 56 (86.2)  | 139 (83.2)  | 195 (84.1)    |
| Degludec (Tresiba®)      |                                | 9 (13.8)   | 11 (6.6)    | 20 (8.6)      |
| Detemir (Levemir®)       |                                | 1 (1.5)    | 4 (2.4)     | 5 (2.2)       |
| Glargine                 |                                | 47 (72.3)  | 124 (74.3)  | 171 (73.7)    |
| (Abasaglar®)             |                                | 1 (1.5)    | 13 (7.8)    | 14 (6.0)      |
| (Lantus®)                |                                | 15 (23.1)  | 54 (32.3)   | 69 (29.7)     |
| (Toujeo®)                |                                | 31 (47.7)  | 58 (34.7)   | 89 (38.4)     |
| Human (Insulatard NPH®)  |                                | -          | 2 (1.2)     | 2 (0.9)       |
| Lispro (Humalog basal®)  |                                | -          | 1 (0.6)     | 1 (0.4)       |
| **Noninsulin treatments**|                                |            |             |               |
| Total noninsulin antidiabetics |                                | 11 (16.9)  | 121 (72.5)  | 132 (56.9)    |
| Total metformin          |                                | 7 (10.8)   | 89 (53.3)   | 96 (41.4)     |
| Total canagliflozin      |                                | -          | 6 (3.6)     | 6 (2.6)       |
| Total dapagliflozin      |                                | 3 (4.6)    | 16 (9.6)    | 19 (8.2)      |
| Total empagliflozin      |                                | 3 (4.6)    | 19 (11.4)   | 22 (9.5)      |
| Total linagliptin        |                                | 1 (1.5)    | 23 (13.8)   | 24 (10.3)     |
| Total sitagliptin        |                                | -          | 20 (12.0)   | 20 (8.6)      |
| Total vildagliptin       |                                | -          | 12 (7.2)    | 12 (5.2)      |
| AGI (repaglinide)        |                                | -          | 6 (3.6)     | 6 (2.6)       |
| DPP4 inhibitors          |                                | 1 (1.5)    | 27 (16.2)   | 28 (12.1)     |
| Variable                     | Prescription                          | T1D (N=65) | T2D (N=167) | Total (N=232) |
|------------------------------|---------------------------------------|------------|-------------|---------------|
| Alogliptin                   | -                                     | 1 (0.6)    | 1 (0.4)     |               |
| Linagliptin                  | 1 (1.5)                               | 19 (11.4)  | 20 (8.6)    |               |
| Sitagliptin                  | -                                     | 5 (3.0)    | 5 (2.2)     |               |
| Vildagliptin                 | -                                     | 2 (1.2)    | 2 (0.9)     |               |
| **DPP4 inhibitors + metformin** | -                                    | 31 (18.6)  | 31 (13.4)   |               |
| Alogliptin + metformin       | -                                     | 1 (0.6)    | 1 (0.4)     |               |
| Linagliptin + metformin      | -                                     | 5 (3.0)    | 5 (2.2)     |               |
| Sitagliptin + metformin      | -                                     | 15 (9.0)   | 15 (6.5)    |               |
| Vildagliptin + metformin     | -                                     | 10 (6.0)   | 10 (4.3)    |               |
| **GLP-1 RAs**                | -                                     | 16 (9.6)   | 16 (6.9)    |               |
| Dulaglutide                  | -                                     | 10 (6.0)   | 10 (4.3)    |               |
| Exenatide                    | -                                     | 3 (1.8)    | 3 (1.3)     |               |
| Liraglutide                  | -                                     | 3 (1.8)    | 3 (1.3)     |               |
| Metformin                    | 5 (7.7)                               | 40 (24.0)  | 45 (19.4)   |               |
| **SGLT2 inhibitors**         | 4 (6.2)                               | 21 (12.6)  | 25 (10.8)   |               |
| Canagliflozin                | -                                     | 3 (1.8)    | 3 (1.3)     |               |
| Dapagliflozin                | 2 (3.1)                               | 8 (4.8)    | 10 (4.3)    |               |
| Empagliflozin                | 2 (3.1)                               | 10 (6.0)   | 12 (5.2)    |               |
| **SGLT2 inhibitors + metformin** | 2 (3.1)                       | 21 (12.6)  | 23 (9.9)    |               |
| Canagliflozin + metformin    | -                                     | 3 (1.8)    | 3 (1.3)     |               |
| Dapagliflozin + metformin    | 1 (1.5)                               | 8 (4.8)    | 9 (3.9)     |               |
| Empagliflozin + metformin    | 1 (1.5)                               | 10 (6.0)   | 11 (4.7)    |               |
| **Sulfonylureas**            | -                                     | 4 (2.4)    | 4 (1.7)     |               |
| Glibenclamide                | -                                     | 1 (0.6)    | 1 (0.4)     |               |
| Gliclazide                   | -                                     | 3 (1.8)    | 3 (1.3)     |               |

Multiple responses were permitted. Percentages were calculated over the total patients in each column.

*a* No Fiasp® prescriptions were reported

*b* Alone or in combination
AGI, alpha-glucosidase inhibitors; DPP4, dipeptidyl peptidase 4; GLP-1 RA, glucagon-like peptide-1 receptor agonist; IL200, insulin lispro 200 U/mL; NPH, neutral protamine Hagedorn; SGLT2, sodium glucose co-transporter 2; T1D, ty